

230 N. Main St. Dayton, OH 45402 | 833-230-2005 | CareSourcePASSE.com

Re: Summary of Formulary/Prior Authorization Changes Effective October 1, 2022

Dear Health Partner,

We are dedicated to partnering with you in the most effective way to manage our members' care. CareSource PASSE complies with Arkansas Medicaid's Evidence-Based Preferred Drug List (PDL) and also routinely reviews medications not found on Arkansas Medicaid's PDL. We encourage you to actively work with your CareSource PASSE patients in advance of the effective date above to ensure a smooth transition if necessary.

SUMMARY OF CHANGES TO THE ARKANSAS MEDICAID PDL EFFECTIVE OCTOBER 1, 2022:

AUTHORIZATION/CRITERIA ON THE PDL EFFECTIVE OCTOBER 1, 2022.			
Product Name	Strength(s)	Notes If Applicable	
Aimovig	70 mg/mL, 140	Updated criteria for migraine prevention	
Autoinjector	mg/mL		
Ajovy Autoinjector,	225 mg/1.5 mL	Updated criteria for migraine prevention	
Syringe			
Asmanex Twisthaler	110 mcg, 220 mcg	Will not require prior authorization	
Belsomra Tablet	5 mg, 10 mg, 15 mg, 20 mg	Age limit of ≥18 years old added	
Budesonide Ampules	0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL	Added criteria for eosinophilic esophagitis	
Byetta Pen	5 mcg, 10 mcg	Updated criteria	
Dayvigo Tablet	5 mg, 10 mg	Age limit of ≥18 years old added	
Doxepin Tablet	3 mg, 6 mg	Age limit of ≥18 years old added	
Dupixent Pen, Syringe	100 mg/0.67 mL, 200 mg/1.14 mL, 300 mg/2 mL	Added criteria for eosinophilic esophagitis	
Edluar Sublingual Tablet	5 mg, 10 mg	Age limit of ≥18 years old added	
Emgality Pen, Syringe	100 mg/mL, 120 mg/mL	Updated criteria for migraine prevention	
Estazolam Tablet	1 mg, 2 mg	Age limit of ≥18 years old added	
Eszopiclone Tablet	1 mg, 2 mg, 3 mg	Age limit of ≥18 years old added	
Farxiga Tablet	5 mg, 10 mg	Updated criteria	
Flovent HFA	44 mcg, 110 mcg, 220 mcg	Will not require prior authorization (Brand)	
Flurazepam Capsule	15 mg, 30 mg	Age limit of ≥18 years old added	
Jardiance Tablet	10 mg, 25 mg	Updated criteria	
Quviviq Tablet	25 mg, 50 mg	Age limit of ≥18 years old added	

THE FOLLOWING MEDICATIONS WILL HAVE A CHANGE IN PRIOR AUTHORIZATION/CRITERIA ON THE PDL EFFECTIVE OCTOBER 1, 2022.

CareSourcePASSE.com

Product Name	Strength(s)	Notes If Applicable
Ramelteon Tablet	8 mg	Age limit of ≥18 years old added
Temazepam Capsule	7.5 mg, 15 mg, 22.5 mg, 30 mg	Age limit of ≥18 years old added
Victoza Pen	18 mg/3 mL	Updated criteria
Zalepion Capsule	5 mg, 10 mg	Age limit of ≥18 years old added
Zolpidem Extended Release Tablet	6.25 mg, 12.5 mg	Age limit of ≥18 years old added
Zolpidem Sublingual Tablet	1.75 mg, 3.5 mg	Age limit of ≥18 years old added
Zolpidem Tablet	5 mg, 10 mg	Age limit of ≥18 years old added

SUMMARY OF CHANGES TO PRODUCTS NOT ON THE ARKANSAS MEDICAID PDL EFFECTIVE OCTOBER 1, 2022:

THE FOLLOWING MEDICATIONS HAVE A CHANGE IN PRIOR AUTHORIZATION/CRITERIA EFFECTIVE OCTOBER 1, 2022.

Product Name	Strength(s)	Notes If Applicable
Camzyos Capsule	2.5 mg, 5 mg, 10	New criteria
	mg, 15 mg	
Dihydroergotamine	0.5 mg/spray	Updated criteria for acute migraine treatment
Nasal Spray		
Elyxyb Solution	120 mg/4.8 mL	Updated criteria for acute migraine treatment
Feiba NF Vial	500 unit, 1,000	Updated criteria
	unit, 2,500 unit	
Hemlibra Vial	30 mg/mL, 60	Updated criteria
	mg/0.4 mL, 105	
	mg/0.7 mL, 150	
	mg/mL	
	U	Lindeted eviteria
Novoseven RT Vial	1 mg, 2 mg, 5 mg,	Updated criteria
	8 mg	
Nurtec ODT Tablet	75 mg	Updated criteria for acute migraine treatment
		and migraine prevention
Qulipta Tablet	10 mg, 30 mg, 60	Updated criteria for migraine prevention
-	mg	
Reyvow Tablet	50 mg, 100 mg	Updated criteria for acute migraine treatment
Sevenfact Vial	1 mg, 5 mg	Updated criteria
Trudhesa Nasal	0.725 mg/spray	Updated criteria for acute migraine treatment
Spray		
Ubrelvy Tablet	50 mg, 100 mg	Updated criteria for acute migraine treatment
Vijoice Daily Dose	50 mg, 125 mg,	New criteria for PIK3CA-Related Overgrowth
Pack, Tablet	250 mg	Spectrum (PROS)
•	· · ·	



230 N. Main St. Dayton, OH 45402 | 833-230-2005 | CareSourcePASSE.com

What you should know

We know patient care is of the utmost importance to you. We are notifying our members of this change to help ensure their treatment plan is maintained. We have asked our members to contact their prescriber if they have questions.

Additional Resources

For the most up-to-date information, please utilize the Formulary resources available at **CareSourcePASSE.com**. You can also access the complete PDL at **CareSourcePASSE.com** by clicking on:

- Providers
- Tools & Resources
- Drug Formulary

We recognize each patient is unique and we appreciate your partnership in making this a successful transition. We are here to help you with any questions. Call CareSource PASSE Provider Services at 1-833-230-2100 Monday through Friday, 8 a.m. to 5 p.m. CST. Thank you for being a CareSource PASSE health partner.

Sincerely,

CareSource PASSE

AR-PAS-P-1135301-V.3